View the 2014 Annual Meeting Abstracts on our Online Conference Planner or the Red Journal.
View the 2014 Digital Poster Library (ePosters). The ePoster library contains the posters for all abstracts presented in the Digital Poster sessions.
ASTRO's Annual Meeting is the premier radiation oncology scientific event in the world and draws more than 11,000 attendees each year. During the 2014 Annual Meeting, we will highlight science that showcases how technology and biology advance the field and improve patient outcomes and quality of life.
The scientific program will continue to be the ideal platform to bring together clinicians, scientists and researchers from all oncology disciplines to exchange ideas, promote multidisciplinary care and address the educational and professional development interests of our attendees. Scientific and educational sessions will cover specific clinical areas including breast, central nervous system, gastrointestinal, genitourinary, gynecologic, head and neck, lymphoma, musculoskeletal, pediatric, sarcoma and thoracic cancers. Radiation biology and radiation physics concepts will be explored in their own tracks.
The Annual Meeting will feature a continued emphasis on patient quality and safety issues in the delivery of radiation therapy in the areas of treatment techniques, equipment, terminology and professional responsibilities. Program content has been designed to address specific documented and clinically important practice gaps in physician knowledge and competence.
Conflict of Interest Policy
ASTRO is an accredited provider of continuing medical education and adheres to the policies and standards set forth by the Accreditation Council for Continuing Medical Education (ACCME).
To ensure its compliance, ASTRO expects that the content and related materials will promote improvements or quality in health care and not a specific proprietary business interest or commercial bias. We employ several strategies to ensure absence of bias:
- Disclosure of financial interests and identification and management of potential conflicts. It is the responsibility of the first author to obtain disclosure information from all co-authors and to report this information electronically during the abstract submission.
- A balanced view of therapeutic options will be given.
- A scientifically rigorous review.
- Use of generic names to contribute to impartiality. If trade names are included in your presentation, trade names for several companies should be used where available.